weiguo2122
☆    

2024-06-26 22:17
(379 d 13:07 ago)

Posting: # 24040
Views: 2,450
 

 BE between one injection vs multiple injection products [Design Issues]

Hi, Dear all,
A product A currently is injected weekly for 4 weeks as one treatment term, we would have a slowly release product A (slow-A), which will be injected monthly. Then we would like to access the BE of A injected 4 time vs slow-A injected 1 time. How is this type of BE between one injection vs multiple injection conducted?

Cmax?

sum of AUCA1-4 vs AUC_slow-A?

Is there any guidance from FDA or EMA.

Any help is greatly appreciated.
weiguo2122
☆    

2024-06-27 17:07
(378 d 18:17 ago)

@ weiguo2122
Posting: # 24044
Views: 1,943
 

 BE between one injection vs multiple injection products

That should not be a BE study? Then what should be considered when we develop product from daily injection to weekly as well as weekly to monthly?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]
UA Flag
Activity
 Admin contact
23,432 posts in 4,931 threads, 1,671 registered users;
133 visitors (0 registered, 133 guests [including 62 identified bots]).
Forum time: 11:24 CEST (Europe/Vienna)

It has yet to be proven
that intelligence has any survival value.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5